Inhibrx Inc (INBX)
34.46
+0.11
(+0.32%)
USD |
NASDAQ |
May 08, 16:00
34.46
0.00 (0.00%)
After-Hours: 16:50
Inhibrx Research and Development Expense (Quarterly): 82.09M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 82.09M |
| September 30, 2023 | 38.06M |
| June 30, 2023 | 34.11M |
| March 31, 2023 | 37.39M |
| December 31, 2022 | 30.45M |
| September 30, 2022 | 24.93M |
| June 30, 2022 | 29.91M |
| March 31, 2022 | 24.90M |
| December 31, 2021 | 18.62M |
| September 30, 2021 | 18.48M |
| June 30, 2021 | 17.90M |
| Date | Value |
|---|---|
| March 31, 2021 | 16.44M |
| December 31, 2020 | 17.67M |
| September 30, 2020 | 19.84M |
| June 30, 2020 | 18.97M |
| March 31, 2020 | 17.02M |
| December 31, 2019 | 12.28M |
| September 30, 2019 | 12.78M |
| June 30, 2019 | 12.17M |
| March 31, 2019 | 10.66M |
| June 30, 2018 | 8.495M |
| March 31, 2018 | 10.78M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
12.17M
Minimum
Jun 2019
82.09M
Maximum
Dec 2023
25.47M
Average
18.97M
Median
Jun 2020
Research and Development Expense (Quarterly) Benchmarks
| Axonics Inc | 11.06M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |
| Theriva Biologics Inc | 4.196M |